NCT06544655 2026-04-17
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Active not recruiting
Clinical Trials
59 trialsNCT06049576 2026-04-15
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02453620 2026-04-13
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02496208 2026-04-13
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03502733 2026-04-13
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03816358 2026-04-13
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04652960 2026-04-13
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02393625 2026-04-02
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
Novartis
Phase 1 Active not recruiting
NCT04835805 2026-03-30
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
Genentech, Inc.
Phase 1 Active not recruiting
NCT04930783 2026-03-25
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03044613 2026-03-23
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT04387084 2026-03-23
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT04514484 2026-03-23
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04420975 2026-03-10
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04013542 2026-03-05
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05122546 2026-03-05
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03223155 2026-03-04
COSINR
University of Chicago
Phase 1 Active not recruiting
NCT04109729 2026-03-02
Rad2Nivo
University of Utah
Phase 1 Active not recruiting
NCT04336241 2026-02-27
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune Inc.
Phase 1 Active not recruiting
NCT04735978 2026-02-27
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Replimune Inc.
Phase 1 Active not recruiting
NCT04606316 2026-02-17
Surgical Nivolumab And Ipilimumab For Recurrent GBM
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03628209 2026-02-05
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT06880549 2026-02-05
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT05867121 2026-02-02
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech, Inc.
Phase 1 Active not recruiting
NCT02989636 2026-01-06
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT03929029 2026-01-05
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03884998 2025-12-30
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05327270 2025-12-26
Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04658147 2025-12-18
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT07031765 2025-12-18
Peds CHAMP1ON
University of Florida
Phase 1 Active not recruiting
NCT06764771 2025-12-17
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Bristol-Myers Squibb
Phase 1 Active not recruiting
NCT04117087 2025-12-03
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT04495257 2025-10-30
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
Yale University
Phase 1 Active not recruiting
NCT02817633 2025-10-28
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Tesaro, Inc.
Phase 1 Active not recruiting
NCT03589339 2025-10-24
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Nanobiotix
Phase 1 Active not recruiting
NCT02914405 2025-10-22
MiniVan
University Hospital Southampton NHS Foundation Trust
Phase 1 Active not recruiting
NCT03816332 2025-10-09
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04162015 2025-09-12
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05721846 2025-09-12
CheckVAC
Herlev Hospital
Phase 1 Active not recruiting
NCT02879695 2025-08-15
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02099058 2025-08-14
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT05262556 2025-08-07
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT05341349 2025-07-30
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
Phase 1 Active not recruiting
NCT03843294 2025-07-03
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
Children's National Research Institute
Phase 1 Active not recruiting
NCT04047706 2025-06-29
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 1 Active not recruiting
NCT04024878 2025-06-18
NeoVax With Nivolumab in Patients With Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03655002 2025-06-17
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03155061 2025-06-05
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting